We are live on ! Find out more
OKUR

OnKure Therapeutics
OKUR

33 hedge funds and large institutions have $43.3M invested in OnKure Therapeutics in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 12 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.37% less ownership

Funds ownership: 7.07% → 6.7% (-0.37%)

15% less capital invested

Capital invested by funds: $50.8M → $43.3M (-$7.49M)

20% less funds holding

Funds holding: 41 → 33 (-8)

50% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 14

58% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 12

Holders
33
Holders Change
-8
Holders Change %
-19.51%
% of All Funds
0.56%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
7
Increased
5
Reduced
12
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$402K
2
Millennium Management
Millennium Management
New York
+$139K
3
UBS Group
UBS Group
Switzerland
+$124K
4
Barclays
Barclays
United Kingdom
+$117K
5
E
Ergoteles
New York
+$98.7K

Top Sellers

Rank Fund Capital Flow
1
TCM
Tybourne Capital Management
Hong Kong
-$2.06M
2
BlackRock
BlackRock
New York
-$684K
3
State Street
State Street
Massachusetts
-$170K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$158K
5
Northern Trust
Northern Trust
Illinois
-$132K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$12.7M – – –
NHAS
2
Novo Holdings A/S
Denmark
$9.09M – – –
RVM
3
RiverVest Venture Management
Missouri
$6.38M – – –
A
4
Abingworth
United Kingdom
$5.41M – – –
RSCM
5
Rock Springs Capital Management
Maryland
$3.03M – – –
ACM
6
Aisling Capital Management
New York
$2.35M – – –
Franklin Resources
7
Franklin Resources
California
$1.08M -$2.1K -90 -0.2%
Vanguard Group
8
Vanguard Group
Pennsylvania
$845K -$97.9K -4,207 -12%
IC
9
Ikarian Capital
Texas
$491K – – –
Citadel Advisors
10
Citadel Advisors
Florida
$457K +$402K +17,259 New
BCM
11
Bridgeway Capital Management
Texas
$186K -$69.8K -3,000 -30%
Millennium Management
12
Millennium Management
New York
$158K +$139K +5,969 New
UBS Group
13
UBS Group
Switzerland
$145K +$124K +5,348 +4,998%
Barclays
14
Barclays
United Kingdom
$143K +$117K +5,039 +1,415%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$141K -$158K -6,780 -56%
E
16
Ergoteles
New York
$112K +$98.7K +4,240 New
Federated Hermes
17
Federated Hermes
Pennsylvania
$80K +$30.3K +1,300 +76%
BlackRock
18
BlackRock
New York
$61K -$684K -29,402 -93%
Renaissance Technologies
19
Renaissance Technologies
New York
$61K +$53.5K +2,300 New
Bank of America
20
Bank of America
North Carolina
$60K -$42.8K -1,840 -45%
Commonwealth Equity Services
21
Commonwealth Equity Services
Massachusetts
$59K – – –
NM
22
Newtyn Management
New York
$56K +$48.8K +2,098 New
Morgan Stanley
23
Morgan Stanley
New York
$54K +$35.1K +1,509 +279%
BFM
24
Boothbay Fund Management
New York
$47K – – –
State Street
25
State Street
Massachusetts
$43K -$170K -7,285 -82%
1
2

OKUR Hedge Fund Activity: Q2 2022 in Review

33 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q2 2022, worth a combined $43.3M — down 15% from $50.8M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of OKUR and 7 opened new positions — a net loss of 7 holders — while 12 trimmed existing stakes and 5 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $402K. The largest seller was Tybourne Capital Management, exiting entirely with an estimated $2.06M sold.

  • 33 institutional investors held OnKure Therapeutics (OKUR) as of Q2 2022, down from 41 in Q1 2022.
  • Funds reported $43.3M of OnKure Therapeutics stock for Q2 2022, down 15% quarter-over-quarter.
  • 7 funds opened new OnKure Therapeutics positions in Q2 2022 and 14 closed out, a net change of -7 holders.
  • The largest OnKure Therapeutics buyer in Q2 2022 was Citadel Advisors, an estimated $402K added.
  • The largest OnKure Therapeutics seller in Q2 2022 was Tybourne Capital Management, an estimated $2.06M sold.

Based on aggregated 13F filings for Q2 2022.